Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tania Jain

Showing results (111-120 of 118) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 118 results.
Blood|March 19, 2025
Role of allo-HCT in "nonclassical" MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMTNicola Polverelli, Juan Carlos Hernandez-Boluda, Francesco Onida, et al.
Transplantation and Cellular Therapy|August 17, 2021
Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic SyndromesBetül Oran, Kwang Woo Ahn, Caitrin Fretham, et al.
Nature Medicine|March 15, 2022
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapyMelody Smith, Anqi Dai, Guido Ghilardi, et al.
Blood Advances|May 3, 2023
A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysisRoni Tamari, Donal P McLornan, Kwang Woo Ahn, et al.
Blood Advances|June 25, 2024
Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR studyTania Jain, Noel Estrada-Merly, M Queralt Salas, et al.
Transplantation and Cellular Therapy|July 26, 2021
Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular TherapyMohamed A Kharfan-Dabaja, Ambuj Kumar, Ernesto Ayala, et al.
Blood Advances|May 9, 2020
Survival following allogeneic transplant in patients with myelofibrosisKrisstina Gowin, Karen Ballen, Kwang Woo Ahn, et al.
Blood Advances|July 15, 2020
Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR reportZheng Zhou, Rajneesh Nath, Jan Cerny, et al.
Pageof 12

Showing results (111-120 of 118) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 118 results.
Blood|March 19, 2025
Role of allo-HCT in "nonclassical" MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMTNicola Polverelli, Juan Carlos Hernandez-Boluda, Francesco Onida, et al.
Transplantation and Cellular Therapy|August 17, 2021
Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic SyndromesBetül Oran, Kwang Woo Ahn, Caitrin Fretham, et al.
Nature Medicine|March 15, 2022
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapyMelody Smith, Anqi Dai, Guido Ghilardi, et al.
Blood Advances|May 3, 2023
A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysisRoni Tamari, Donal P McLornan, Kwang Woo Ahn, et al.
Blood Advances|June 25, 2024
Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR studyTania Jain, Noel Estrada-Merly, M Queralt Salas, et al.
Transplantation and Cellular Therapy|July 26, 2021
Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular TherapyMohamed A Kharfan-Dabaja, Ambuj Kumar, Ernesto Ayala, et al.
Blood Advances|May 9, 2020
Survival following allogeneic transplant in patients with myelofibrosisKrisstina Gowin, Karen Ballen, Kwang Woo Ahn, et al.
Blood Advances|July 15, 2020
Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR reportZheng Zhou, Rajneesh Nath, Jan Cerny, et al.
Pageof 12